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Abstract
In the approval process for new weight management therapies, regulators typically require estimates of effect size. Usually,
as with other drug evaluations, the placebo-adjusted treatment effect (i.e., the difference between weight losses with
pharmacotherapy and placebo, when given as an adjunct to lifestyle intervention) is provided from data in randomized
clinical trials (RCTs). At first glance, this may seem appropriate and straightforward. However, weight loss is not a simple
direct drug effect, but is also mediated by other factors such as changes in diet and physical activity. Interpreting observed
differences between treatment arms in weight management RCTs can be challenging; intercurrent events that occur after
treatment initiation may affect the interpretation of results at the end of treatment. Utilizing estimands helps to address these
uncertainties and improve transparency in clinical trial reporting by better matching the treatment-effect estimates to the
scientific and/or clinical questions of interest. Estimands aim to provide an indication of trial outcomes that might be
expected in the same patients under different conditions. This article reviews how intercurrent events during weight
management trials can influence placebo-adjusted treatment effects, depending on how they are accounted for and how
missing data are handled. The most appropriate method for statistical analysis is also discussed, including assessment of the
last observation carried forward approach, and more recent methods, such as multiple imputation and mixed models for
repeated measures. The use of each of these approaches, and that of estimands, is discussed in the context of the SCALE
phase 3a and 3b RCTs evaluating the effect of liraglutide 3.0 mg for the treatment of obesity.
Introduction
Research programs investigating weight-loss interventions
are currently based almost exclusively on randomized
clinical trials (RCTs) to ascertain the efficacy and safety of a
treatment. Randomization provides the highest level of
evidence for these evaluations, by ensuring that neither the
intervention being investigated nor the comparator by
default is favored through potential effect modifiers at the
time of randomization. However, effect modifiers or con-
founding factors may emerge after randomization that affect
the estimated differences between the treatment groups.
Hence, while the integrity of the randomization must be
respected in any analysis of an RCT, the question on what
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to do about post-randomization effect modifiers remains and
must be discussed.
Regulators require estimates of the treatment effect to be
reported, usually provided as the placebo-adjusted mean
(the difference in total weight loss between treatment arms)
[1, 2]. At first glance, this may seem an appropriate and
straightforward way to quantify the treatment effect, but
there are several reasons why the placebo-adjusted effect
sizes of a drug in RCTs do not necessarily indicate the
effect sizes that are achieved in real-life patient manage-
ment. For example, pharmacotherapy for obesity produces
weight loss not only by a simple drug action, but by
increasing the extent to which individuals can make
changes in their diets and physical activities. Importantly,
participants in weight management RCTs are seeking the
effect of the treatment, and can themselves see their pro-
gress with weight change, which can alter their adherence
and other behaviors. In addition, there are many external
factors that can influence weight change, so observed dif-
ferences in RCTs should be interpreted in the light of
various factors or events that can occur during a trial. For
example, individuals receiving placebo may not experience
satisfactory weight loss and as a result may adopt another
behavioral measure or weight-loss medication (other than
the active medication) during the trial, and thus experience
a larger reduction in body weight than if they had only
received placebo. Events that occur during a trial that may
influence interpretation of the results are termed inter-
current events [3].
In addition to intercurrent events, missing body weight
assessments at the end of treatment need to be handled in
the statistical analysis. The various approaches to handling
missing data each have their own advantages and dis-
advantages, and will in some cases rely on unverifiable
assumptions [4]. Analytical methods required by regulatory
bodies, such as the US Food and Drug Administration
(FDA) and the European Medicines Agency (EMA), may
be appropriate from a regulatory perspective, but may not
provide the most useful information to inform clinicians
about the treatment effects that could be expected in their
patients. Furthermore, data presented in prescribing infor-
mation and scientific publications for the same product may
have been analyzed using different statistical approaches
and thereby yield different efficacy results, making it
challenging to communicate the treatment effect to the
relevant audiences.
There is a need for greater transparency and alignment in
how weight management RCTs are designed, conducted,
and reported to help different stakeholders (e.g., clinicians,
regulatory bodies, prescribers, patients, payers, and guide-
line developers) understand how estimated treatment effects
should be interpreted. One way to address this need is to
utilize estimands. The estimand concept [3] provides a
framework to align trial design and objectives to ensure that
the estimated treatment effect is relevant to the scientific
question(s) of interest. The attributes that determine how the
treatment effect must be interpreted, and thus define an
estimand, are: (i) the treatment condition of interest; (ii) the
population to be studied; (iii) the endpoint of interest
(including whether a participant experiences an intercurrent
event); and (iv) the population-level summary (i.e., how the
treatment effect is to be determined). Estimands aim to
provide information for the target population on what the
efficacy outcomes might be expected to be in the same
patients under different conditions [3]. In addition to stating
that estimands should be used, the International Council for
Harmonisation of Technical Requirements for Pharmaceu-
ticals for Human Use (ICH) guidelines also emphasize the
importance of considering intercurrent events when defining
the scientific question of interest and underline key princi-
ples for handling missing data [3].
In line with the EMA and FDA regulatory guidelines
[5, 6], ongoing and newly initiated weight management
trials will be required to report results using estimands. The
SCALE (Satiety and Clinical Adiposity-Liraglutide Evi-
dence in individuals with and without diabetes) phase 3b
trials investigating efficacy and safety of liraglutide 3.0 mg
as an adjunct to diet and lifestyle advice for weight man-
agement have recently been published with two estimands
[7, 8]. Similarly, clinical trial programs for weight man-
agement drugs in development, such as the semaglutide
2.4 mg once-weekly STEP (Semaglutide Treatment Effect
in People with obesity) trial program [9–16] are planned to
report results utilizing estimands.
In this review, we discuss how intercurrent events can
affect the estimation and interpretation/quantification of a
treatment effect in weight management trials; how approa-
ches for handling missing data have evolved over the last
decade; and implications for interpreting clinical data from
weight management RCTs. We examine these issues using
the SCALE phase 3a clinical trial program as an example
and address how the use of estimands may help provide
greater transparency in clinical trial reporting.
Intercurrent events in weight management
trials and their impact on data analysis and
interpretation
RCTs are the gold standard for demonstrating a treatment’s
efficacy and safety, where many factors are standardized
through inclusion criteria and guidance on what to do during
the trial (i.e., the trial protocol). Randomization of trial par-
ticipants into treatment groups aims to avoid selection bias
and to balance the treatment groups at baseline. However,
after randomization, clinical trial participants can experience
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intercurrent events that affect the endpoint of interest and
its interpretation, and they may be unequal between
randomized treatment groups (Fig. 1). It is therefore
important to understand intercurrent events that are
common during weight management trials and how they
may influence the analysis and interpretation of results.
It is vital to recognize that in weight management RCTs,
the treatment effect (weight loss) is desired by the trial
participants, and that it is not only a direct pharmacological
effect of trial product but is also mediated by changes in
eating and/or activity behaviors. Trial participants can see,
and feel, the effect of a treatment and can become aware of
their allocation to active or placebo arms. Participants
allocated to placebo groups are increasingly likely to
withdraw from treatment or to adopt additional measures
aimed at weight loss. During a trial, participants may thus
discontinue their randomized treatment for various reasons,
such as lack of tolerability, disappointment in the weight
loss achieved, relocation, health complications, or initiation
of other medication, etc. In addition, some participants
might be switched to a different weight-loss medication (or
even undergo bariatric surgery) if they do not achieve
weight reductions as sought for medical or personal reasons,
or as expected from the protocol [17]. Smoking aggravates
most medical complications of obesity, and cessation is
often concurrently recommended; however, smoking ces-
sation usually leads to weight gain, often substantial
[18, 19], and could therefore differentially affect body
weight if participants decided to stop smoking during the
trial [19–21]. Smoking cessation may be more successful
with an active weight-loss medication than with a placebo,
thus reducing the apparent effect size of an active medica-
tion. Such intercurrent events will likely result in different
placebo-adjusted treatment effects than if they had not
occurred and raise questions about how these events should
be accounted for and how trial results should be interpreted
(Table 1).
When estimating the placebo-adjusted weight loss in a
clinical trial, investigators need to decide whether weight
measurements taken after intercurrent events should be
included or excluded from a particular analysis. For
example, including weight measurements in the analysis
for those who discontinued treatment reflects how, in a
real-world situation, adherence to any treatment is likely to
vary between patients. If post-discontinuation weight
measurements were excluded from a particular analysis
and replaced by model predictions, the treatment effect
would represent a hypothetical situation in which all par-
ticipants tolerated and adhered to the treatment. Such
hypothetical estimation may not represent a real-world
situation but provides information, and a different per-
spective, on the extent of weight loss that can be achieved
in the target population if the drug is taken as intended and
no intercurrent events occur.
Which intercurrent events should be accounted for
in weight management RCTs?
Intercurrent events are not limited to the examples discussed
so far, and it may not always be clear what should be
categorized as an intercurrent event. For instance, trial
participants might seek other weight-loss interventions such
as joining a gym or a commercial weight-loss program.
Investigators would need to decide whether engaging in
these activities would be part of the diet and exercise
regimen detailed in the trial protocol or if such activities
should be regarded as intercurrent events that need to be
addressed in the statistical analysis. These alternative
weight-loss interventions may not be equally available or
affordable to people with obesity in routine clinical practice,
but might be adopted more by trial participants if they are
made available as part of the trial. When designing a trial,
consideration must be given to scenarios that could be
identified as intercurrent events and which of these events
Fig. 1 Intercurrent events and their implications in weight man-
agement clinical trials. CI confidence interval, ETD estimated treat-
ment difference. aIntercurrent events are likely to be unbalanced
between treatment arms, potentially introducing bias. bAdopting other
weight-loss medication recorded as concomitant medication during the
trial. Non-pharmacological measures could also be considered, e.g.,
actively engaging in additional weight-loss programs such as joining a
gym or commercial weight-loss program, or bariatric surgery.
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would be relevant to that particular trial. Discontinuation of
randomized medication is common and may substantially
affect weight loss; consequently, treatment discontinuation
should always be handled as an intercurrent event. In con-
trast, intercurrent events such as smoking cessation or
switching to another approved weight-loss medication
would only need to be accounted for in trials in which these
phenomena are expected to have a substantial effect on the
endpoint in question, for example, if the intercurrent event
is common, or if it occurs at different rates between active
and placebo arms. Crucially, intercurrent events should
be prespecified and the strategy for analyzing the data in the
Table 1 Intercurrent events in weight management clinical trials, their potential impact on body weight, and interpretation of results.
Intercurrent event Impact on body weight Implicaons for the 
placebo-adjusted 
treatment effect 
Interpretaon of treatment effect when weight measurements 
are included/excluded in analysis 
Included in analysis Exclude from analysis  
Disconnuaon of 
invesgaonal drug due to 
intolerability  
• Weight regain may 
occur if the 
treatment had 
inially resulted in 
weight loss 
Reduced • Reflects how adherence to 
any treatment is likely to 
vary between paents 
• Represents a situaon in 
which people don’t respond 
to, or are unsasfied with, 
their treatment and try 
other medicaons 
• Represents a broad 
populaon in which 
different intercurrent 
events would be likely to 
occur 
• May be of interest to  
policy-makers  
• Represents a hypothecal 
situaon in which all 
parcipants tolerated and 
adhered to treatment, or 
switched to another 
approved medicaon 
• Provides the closest 
esmate of the true 
pharmacological effect of 
the drug but relies on 
assumpons that are not 
always achievable in 
pracce 
Switching to another 
approved weight loss 
medicaon due to lack of 
efficacy 
• More weight loss 
could be observed 
for an individual in 
the placebo arm than 
if they had only 
received placebo 
• For a poor-responder 
receiving the 
invesgaonal drug, 
beer weight loss 
could be achieved 
with another 




Smoking cessaon in the • Potenal weight gain Reduced • Provides informaon on • People who don’t smoke 
acve arm what weight loss could be 
expected with the 
treatment and if smoking 
cessaon occurred 
• May be of interest to 
people who smoke and are 
considering treatment with 
the invesgaonal drug 
would not likely be 
interested in a treatment 
effect that takes into 
account smoking cessaon 
Smoking cessaon in the 
placebo arm 
• Potenal weight gain Increased 
Parcipants in the acve 
arm acvely engage in 
addional weight loss 
programs such as joining a 
gym or commercial weight 
loss program, or make 
weight loss-inducing 
changes to their diet and 
exercise regimes  
• Further weight loss  Increased • Reflects that people may do 
a number of things to 
increase their weight loss 
either as a result of 
becoming encouraged by 
inial success, or 
discouraged by not losing 
weight (e.g. if in placebo 
arm)  
• Only considers the 
treatment effect if people 
don’t take any other 
measures to increase their 
weight loss 
Parcipants in the placebo 
arm acvely engage in 
addional weight loss 
programs such as joining a 
gym or commercial weight 
loss program, or make 
weight loss-inducing 
changes to their diet and 
exercise regimes  
• Weight loss Reduced 
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presence of these events should be relevant to the under-
lying clinical question of the trial.
Missing data in weight management trials
In weight management RCTs, not all participants remain in
the trial for the planned duration (e.g., due to lack of toler-
ability, dissatisfaction with treatment, or being lost to follow
up). In one weight management observational study com-
paring characteristics between completers and non-com-
pleters, dropout rates were reported to be 21% at 1 month
and 57% at 6 months [22]. These losses will result in
missing data if post-dropout measurements are not obtained,
which can reduce statistical power and create challenges in
analyzing and interpreting an incomplete dataset [23].
The problem of missing data is best handled by mini-
mizing the number of subjects lost to follow up through
various means such as trial design (e.g., continuing to col-
lect data for participants even if they discontinue their
randomized treatment), and providing guidance on statis-
tical approaches to handling missing data [24, 25]. For
example, to help ensure that participants attended scheduled
visits, trial protocols for SCALE phase 3a trials of liraglu-
tide 3.0 mg for weight loss included reminders at each visit
to book the next appointment [26, 27]. In the recent SCALE
Intensive Behavioral Therapy phase 3b trial, participants
were encouraged to attend scheduled visits and thus have
their weight measurements recorded regardless of dis-
continuing treatment [8]. To promote participant retention,
the SCALE Insulin phase 3b trial permitted individuals to
stop and restart liraglutide 3.0 mg without re-escalating the
dose, or with re-escalation if three consecutive doses had
been missed [7].
Useful information can be applied from the known effect
of treatment discontinuation at the end of the trial in other
participants. In some cases, it is possible to obtain follow-up
data from other sources, such as routine medical records,
which can inform projections for those who discontinue
early or who are lost to follow up [17, 28]. It might be
expected that participants who drop out of clinical trials of
weight management would not go on to achieve further
weight loss, but some might be successful with their weight
loss outside of the trial setting [28].
Estimating treatment effects: accounting for
intercurrent events and handling missing
data
The ICH recommends the use of estimands in clinical trials
[3]. Utilizing estimands in the context of weight manage-
ment RCTs ensures that anticipated intercurrent events of
relevance, such as smoking cessation, adding or switching
to another approved weight-loss medication, or dis-
continuation, are prespecified.
Different scientific questions may be addressed, and
therefore multiple estimands employed, in a single clinical
trial. The treatment policy estimand strategy, outlined in the
ICH guidelines [3], provides a population-level effect of the
tested therapy, which may be of primary interest to policy-
makers. In contrast, the hypothetical strategy, outlined in the
ICH guidelines [3] (also known as the trial product estimand
in some clinical trials [29]), provides information on the
pharmacological effect of the tested therapy under the
assumption that intercurrent events will not occur. It is
important to ensure that an appropriate description of the
estimands used is provided when weight management RCT
results are communicated. This will help the audience gain a
greater understanding of how the results have been estimated
and how they should be interpreted, and aids comparison of
results with those from other clinical trials. In addition to
estimands, guidelines state that the most appropriate statis-
tical methods should be selected to account for intercurrent
events [3] and missing data [24], so that the treatment effect
of interest is the one that is eventually estimated.
Primary outcomes for RCTs in weight management
include mean weight loss from randomization to end of
treatment and placebo-adjusted weight loss. Mean values
for these outcomes can be calculated from observed data or
from imputed data when there are missing observations. A
completers analysis uses data from a subset of participants
who did not have their endpoint imputed in the primary
analysis and can bypass the issue of missing data. Different
methods of statistical analysis can be employed to estimate
the treatment effect of interest, taking into account inter-
current events and missing data; all could be considered
valid under appropriate circumstances but for different
specific purposes. Such analytical methods include the last
observation carried forward (LOCF), multiple imputation
(MI), and mixed model for repeated measures (MMRMs)
[23]. Statistical tests for whether differences in the follow-
ing treatment effect estimates are significant are not easy to
interpret since the estimates have different interpretations
and provide different clinical perspectives on the treatment
effect. Thus, such tests should be avoided.
Treatment effects based on data obtained from
treatment completers
A frequently used method to estimate the effect in rando-
mized trials is through restricting the analysis set to
comprising only data from patients who continue the ran-
domized treatment until the scheduled end-of-treatment visit
(i.e., treatment completers). This approach simplifies the
statistical analysis and circumvents the problem of missing
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data, and is often thought to provide an estimate of the
pharmacodynamic effect of the intervention under investi-
gation (i.e., the effect of the intervention when used as
intended). However, the underlying causes for discontinu-
ing randomized treatment often depend on the treatment
itself. For instance in the SCALE trials, non-completing
patients typically discontinued liraglutide 3.0 mg due to
tolerability issues, whereas non-completing patients typi-
cally discontinued placebo due to lack of effect, and there
are no strong arguments to suggest that the patients who
discontinued placebo would also have been the patients who
would experience tolerability issues had they been rando-
mized to liraglutide 3.0 mg instead. Hence completer ana-
lyses are subject to different selection mechanisms across
the randomized arms, and consequently violate the integrity
of the randomization. Thus, the completer analysis should
in general be avoided in the reporting of results from ran-
domized trials.
Treatment effects estimated by LOCF-based
analyses
Historically, participants in weight management trials who
discontinued their allocated treatment were often censored
from the trial, resulting in no or few post-discontinuation
weight assessments available for the statistical analysis [24].
This means that the treatment policy estimate of the
placebo-adjusted weight loss could not be obtained without
making extensive and unverifiable assumptions in the sta-
tistical analysis. In some studies, in which treatment dis-
continuation resulted in missing data, post-discontinuation
assessments were imputed using the LOCF approach
[26, 27, 30–32].
The LOCF approach uses the participant’s last observed
value (e.g., body weight at last visit before discontinua-
tion) for the endpoint analysis. The last observed value can
either replace a missing weight assessment for a trial
participant lost to follow up or replace weight assessments
that were taken after discontinuation of the active treat-
ment or placebo, if the participant continued to have
weight assessments taken at pre-determined times while
off treatment. LOCF-based placebo-adjusted weight-loss
estimations can consequently be interpreted in one of two
ways depending on whether LOCF values are used only to
impute missing data, or if they are used to impute missing
data and replace off-treatment values. When imputing
missing data only, the underlying assumption is that body
weight would be unaffected by discontinuation for trial
participants lost to follow up. Participants typically
experience weight regain after discontinuing an effective
treatment [33]; therefore, the assumption of no weight
change post-discontinuation required by this version of the
LOCF approach is unrealistic.
The imputation of missing values and replacing off-
treatment values with the last observation on-treatment
carried forward was the approach used in the SCALE phase
3a weight management publications [26, 27, 32]. In this
approach, the last observation on-treatment carried forward-
based treatment effect can be interpreted as the effect of the
active treatment as long as participants adhered to treatment.
The clinical relevance of the treatment effect estimated
using last observation on-treatment carried forward will be
limited if trial participants tend to discontinue placebo
earlier (or later) than participants in the active treatment
group [4] since there is a risk of not comparing like with
like in this type of analysis. LOCF is of some statistical
value to determine efficacy, but it is of limited value if a
real-life treatment-effect size is required.
Treatment effects estimated using MI
With the increasing computational awareness and capacity
to develop statistical methods that provide more useful
interpretations of the treatment effect, MI methods have
become dominant for the reporting of recent weight man-
agement clinical trials (e.g., semaglutide obesity phase 2
trial [34] and the SCALE phase 3b trials [7, 8]). MI is a
computationally intensive method that can replace missing
weight measurements for participants lost to follow up with
the most plausible value that would have been expected if
the participants had been available for the end-of-trial
weight assessment. Reflecting the uncertainty around what
those values might have been, the MI procedure introduces
random “noise” to the imputed values and generates
numerous new datasets (sometimes hundreds, or even
thousands); hence, the term “multiple” imputation. The
reported placebo-adjusted weight loss is the average of all
these different datasets where, for each dataset, it is esti-
mated with a corresponding 95% confidence interval. The
number of datasets generated should be enough to ensure
that if the MI was to be repeated with a new random noise,
it would provide approximately the same result. The
reported placebo-adjusted weight loss therefore depends on
the collected data and the assumption around the expected
body weight for participants lost to follow up, but does not
depend on the random noise introduced in the imputation
procedure.
A typical assumption for the expected body weight for
participants lost to follow up would be that these partici-
pants, on average, weigh the same at the end of the trial as
comparable participants (by age, sex, occupation, family
structure, etc.) who discontinued treatment at a similar time,
but remained in the trial and thus had a final weight mea-
surement. This kind of MI is sometimes called “sampling
from retrieved dropouts” [4]. Another assumption that is
sometimes used is that participants in the active arm lost to
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follow up would weigh the same, on average, as comparable
participants randomized to placebo. This kind of MI, a more
conservative one, is sometimes called “jump to reference”
[35]. Further approaches toward imputing more realistic
results might include gathering body weight data on drop-
outs from other datasets [28] or potentially by using data
from similar participants in similar trials of the same pro-
duct. Regardless of the assumption used to impute missing
values, the MI approach is considered valid to evaluate a
placebo-adjusted weight loss for a treatment policy estimate
because all available data are used irrespective of what
happens to the participants in the trial (i.e., ignoring inter-
current events).
The supplementation of the available data with imputed
values for participants lost to follow up ensures that all
randomized participants contribute to the effect estimate and
thereby preserves the integrity of the randomization. How-
ever, the imputation in itself does not affect the interpreta-
tion of the placebo-adjusted weight loss.
Treatment effects estimated using MMRM
To supplement the treatment policy estimand, weight
management clinical trials may report the placebo-adjusted
weight loss that is expected when adhering to the treatment
at the investigated dose under the assumption of no inter-
current events [3]. To obtain an estimate of the placebo-
adjusted weight loss if all participants had adhered to the
treatment for the duration of the trial, all weight assessments
after treatment discontinuation are excluded from the ana-
lysis. A frequently used statistical technique to obtain this
estimate with a corresponding 95% confidence interval is
the MMRM.
The MMRM technique borrows information from parti-
cipants who are still adhering to the randomized medication
to obtain a plausible estimate of what the placebo-adjusted
weight loss would have looked like in the hypothetical
situation in which all participants were assumed to adhere to
the assigned treatment to the same degree as those who
were reported to remain adherent throughout the trial. Thus,
the MMRM analysis method estimates the hypothetical
treatment effect under average or normal adherence.
While the assumption of no intercurrent events is often
not entirely realistic, this estimate is the closest we can
currently get to an estimate of the true pharmacological
effect of the drug and is referred to as the trial product
estimate.
Examples of different imputation methods used in
the SCALE phase 3a clinical trial program in weight
management
The different analysis methods discussed here, such as
completers, LOCF, MMRM, and MI, may produce differing
results in a given clinical trial. Here, we present the example
of the SCALE phase 3a program, investigating the efficacy
and safety of liraglutide 3.0 mg for weight management, to
demonstrate this, as different methods of analysis were
required by the EMA compared with the FDA (Table 2). At
the time of the respective regulatory submissions, the EMA
required an LOCF-based approach [36] whereas the FDA
requested an MI approach [37].
The SCALE phase 3a trials discussed in this paper were
designed prior to the recent regulatory requirements for
intercurrent events and hence patients discontinuing ran-
domized injections or violating the protocol were with-
drawn from the trials and only invited in for a landmark
visit to assess the body weight. Hence the estimations of
LOCF and MMRM are based on all data until last obser-
vation on treatment and extrapolating the remaining data
until the planned end of treatment at week 56 (Table 2).
Across three phase 3a SCALE trials [26, 27, 32], the
treatment effects estimated using an LOCF-based approach
were larger than those estimated using an MI approach
Table 2 Difference in treatment effect across the SCALE phase 3a trials estimated by LOCF, MI, and MMRMa.
Estimated treatment difference (placebo-adjusted weight loss) from baseline, % (95% CI)
Completers [38] LOCF-based (EU SmPC) [36] MI (US PI) [37] MMRM [38]
SCALE obesity and prediabetes [27] −5.7 (−6.3, −5.1) −5.4 (5.8, −5.0) −4.5 (−5.2, −3.8) −5.8 (−6.3, −5.3)
SCALE diabetes [26] −4.1 (−5.3, −2.9) −4.0 (−4.8, −3.1) −3.7 (−4.7, 2.7) −4.4 (−5.5, −3.3)b
SCALE maintenance [32] NA −6.1 (−7.5, −4.6) −5.2 (−6.8, −3.5) −6.1 (−7.7, −4.6)
CI confidence interval, EMA European Medicines Agency, EU European Union, FDA Food and Drug Administration, LOCF last observation
carried forward, MI multiple imputation, MMRM mixed model for repeated measures, NA not available, SCALE Satiety and Clinical Adiposity-
Liraglutide Evidence in individuals with and without diabetes, US United States.
aThe estimation of LOCF and MMRM is based on all data until last observation on treatment and extrapolating the remaining data until the planned
end of treatment at week 56. Across the three trials data was extrapolated for ~31% of patients. The amount of extrapolation for each patient was
determined by the time of treatment discontinuation. For the MI-based analysis, only weight assessments missing at week 56 were imputed and
across the trials ~22% of patients had a missing weight assessment at week 56.
bMMRM analysis results for liraglutide 3.0 mg.
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(Table 2). This is because MI-based results reflect the
treatment effect of liraglutide 3.0 mg after 56 weeks in a
population in which some participants discontinued treat-
ment and thus regained body weight, which often occurs
after discontinuation of a weight-loss medication [32, 33].
Therefore, the MI-based analysis takes into account the
effects of treatment discontinuation.
For the purpose of this review, separate MMRM analyses
were performed for the three phase 3a SCALE trials [38]
and, in general, the treatment effects estimated using the
MMRM analysis method were larger than those estimated
using LOCF (Table 2). These larger estimates with the
MMRM analysis method would be expected since MMRM-
based estimates in the SCALE phase 3a trials reflect the
treatment effect of liraglutide 3.0 mg after 56 weeks in a
hypothetical situation in which all randomized patients were
adherent for the planned duration of the trial. In contrast,
LOCF-based estimates in these trials reflect the treatment
effect for liraglutide 3.0 mg up to the time point of dis-
continuation, which could be less than 56 weeks. In addi-
tion, treatment effects estimated using MMRM analyses are
typically larger than those seen with MI analyses since the
MMRM estimates the treatment effect while participants are
adhering to the investigational drug, whereas MI-based
estimates (reflecting the intent-to-treat approach) are irre-
spective of adherence.
Results were similar when sensitivity analyses were
conducted according to completers, MMRM, and MI
(Table 2), indicating the plausibility of the imputation
methods. However, since the completers analysis compro-
mizes the integrity of randomization, interpretation should
be made with caution.
Interpreting trial results in real-world clinical
practice
Treatment effects reported in prescribing information may
differ for the same product depending on the country/region
and the preference of different regulatory agencies for
reporting different analyses. Moreover, analyses and treat-
ment effects in prescribing information may also differ from
those reported in publications in medical journals, where the
choice of analyses may be dictated by authors and/or journal
editors and reviewers. Therefore, clinicians should be aware
of the analyses used when interpreting and trying to compare
data from prescribing information and/or publications.
Real-world evidence can supplement the interpretation of
the placebo-adjusted treatment effect by comparing the
weight loss achieved in the RCT in question with what has
been obtained with the investigational drug in a clinical
database or register. For example, a recent real-world evi-
dence study assessed weight loss in patients receiving
liraglutide 3.0 mg in combination with diet and exercise.
In this study, overall mean weight loss in patients known to
be persistent on liraglutide 3.0 mg was reported to be −6.3%
at 4 months after initiation, −7.1% at 6 months after initia-
tion, and −6.5% at 6 months for all subjects regardless of
persistence [39]. In the phase 3a SCALE trials, participants’
body weight loss with liraglutide 3.0 mg treatment was
6.0–8.0% reported using a LOCF-based analysis method
[26, 27, 32] and 4.9–7.4% using MI [37]. Although it is not
possible to draw direct comparisons from the real-world
evidence study and the RCTs, these examples demonstrate
how reporting the treatment effect from different perspectives
can provide a broader understanding of the weight loss that
can be expected with a medication, and can be useful for
clinicians when assessing pharmacotherapeutic options for
their patients. It is possible that in the future, sources of real-
world evidence data in combination with RCTs will provide
the best estimates of real-life treatment effects.
Reporting results from weight management
clinical trials: moving forward
To avoid selection bias, either all randomized participants
must contribute to the placebo-adjusted weight loss or
comparable groups must be selected in the two treatment
groups in the estimation. LOCF-based statistical approaches
are no longer recommended due to concerns regarding the
plausibility of the assumptions and the potential for bias
[24]. However, the introduction of the estimand concept has
shifted the discussion from potential bias to whether the
LOCF-based estimate of the treatment effect has a clinically
relevant interpretation.
Clinicians and their patients may want to know the
potential effect on weight loss when fully adhering to the
treatment, i.e., the extent of the pharmacological effect.
Likewise, it is useful to estimate weight loss in a population
that might not have been fully adherent due to various rea-
sons, including adverse events and treatment discontinua-
tion, i.e., an average population effect. To provide different
perspectives on the estimated treatment effect in weight
management RCTs, we recommend that future publications
investigating new or already-approved weight-loss medica-
tions report the treatment policy estimand and the trial
product estimand. We also recommend that the estimand
concept should be applied to new trial designs to ensure
transparency and facilitate interpretation of data and com-
parison across trials. While estimands do not solve all pro-
blems of trial design and interpretation, this new concept
will enable trials to be designed more appropriately to obtain
relevant information to address the clinical question(s) of
interest. The SCALE phase 3b clinical trials have been
reported [7, 8], building on the existing evidence for the
efficacy and safety of liraglutide 3.0 mg in weight
930 S. Wharton et al.
management, and are some of the first clinical trials in
weight management to report results using estimands.
Other considerations in weight management
clinical trial reporting
The use of the estimands concept in weight management
trials opens up wider discussions about estimating and
communicating treatment effects for weight management
interventions. The placebo-adjusted weight loss is required
by regulatory bodies to determine whether an investigational
drug is efficacious and tolerable but does not provide suffi-
cient information on the effect size in clinical practice, since
it can never fully account for real-life variability. Therefore,
the placebo-adjusted weight loss does not necessarily provide
the most useful information to translate into clinical practice.
Similarly, clinicians, policy-makers, and people with obesity
may find the mean weight loss of a treatment of little prac-
tical or planning value, while the proportions of people
achieving categorical weight loss of ≥5, ≥10, and ≥15%
might be more relevant to inform real-world clinical practice.
Categorical weight-loss outcomes can also be combined with
treatment adherence in order to estimate the composite effect
of treatment adherence and weight loss. While the aim of this
article is not to review these and other considerations in
detail, the box below represents a compilation of a few
unanswered questions that could guide further academic and
clinical discourse in this area.
Summary
In weight management RCTs, the trial outcome is desired
and visible to participants and treatment blinding may not
be fully achievable with modern potent adjunctive phar-
macotherapy. Intercurrent events such as smoking cessa-
tion, switching to or adding another weight-loss treatment,
or treatment discontinuation, can be unbalanced between
treatment arms and impact the endpoint of interest, and
subsequent data analysis and interpretation. Analyses
should adopt appropriate statistical methods to take into
account intercurrent events and missing data. LOCF-based
methods are no longer considered appropriate for weight
management clinical trials and are being replaced by MI-
and MMRM-based analysis methods. Regulatory require-
ments for the conduct, analysis, and reporting of weight
management trials have evolved in recent years, indicating
the need to provide different perspectives on the treatment
effect when reporting trial results. The use of estimands in
weight management clinical trials is recommended to allow
for easier understanding and interpretation of clinical trial
results among stakeholders. Two estimands will be more
prevalent in future publications for weight management
RCTs: the treatment policy estimand (estimated using MI)
and the trial product estimand (estimated using MMRM).
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Ongoing questions for weight management clinical trial reporting
● In clinical practice, what is the best way for clinicians
to interpret and communicate results from weight-
loss trials?
● Is the proportion of people achieving categorical
weight losses more useful for healthcare payers,
guideline developers, clinicians, and patients than the
placebo-adjusted mean?
● Should trial protocols have clearer definitions of
what are classed as protocol violations, (e.g.,
initiation of another weight-loss intervention) and
how they should be handled in analyses?
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